Skip to content

Transcutaneous Electrical Acupoint Stimulation for Opioid Consumption After Gastrointestinal Laparoscopic Surgery

Effect of Whole-process Transcutaneous Electrical Acupoint Stimulation on Opioid Consumption After Gastrointestinal Laparoscopic Surgery: a Prospective, Randomised, Blinded, Placebo-controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06024200
Enrollment
128
Registered
2023-09-06
Start date
2023-06-02
Completion date
2024-01-30
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transcutaneous Electrical Acupoint Stimulation

Brief summary

The goal of this clinical trial is to evaluate the effect of whole-process transcutaneous electrical acupoint stimulation on opioid consumption after gastrointestinal laparoscopic surgery. All subjects received conventional multimodal analgesia. On this basis, the experimental group received whole-process transcutaneous electrical acupoint stimulation, while the control group received corresponding false stimulation.

Detailed description

Conventional multimodal analgesia protocols as follows: 1. Before the end of the operation, the surgical incision was infiltrated with 0.5% ropivacaine 10 mL locally. 2. Patients were transferred to the PACU and provided with patient-controlled intravenous analgesia with sufentanil for postoperative analgesia. The analgesia devices were set to a concentration of 1ug/mL, with a lockout interval of 15 minutes, and a 3 mL bolus,without an infusion dose. The pump was withdrawn 72h after surgery. 3. Flurbiprofen: 50mg per dose intravenously twice a day for postoperative three days.

Interventions

OTHERtranscutaneous electrical acupoint stimulation

Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.

OTHERtranscutaneous electrical acupoint stimulation sham stimulation

Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.

Sponsors

Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged 18 years or older; * scheduled for elective laparoscopic gastrointestinal surgery; * informed consent; * American Society of Anesthesiologists Physical Status Grades I-III; * body mass index (BMI) between 18.5 kg/m2 and 28 kg/m2

Exclusion criteria

* local skin infection, incision or scar near the study acupoints; * nerve damage in upper or lower limbs; * participation in other clinical trials that influence the evaluation of the results of this study; * inability to understand the Visual Analog Scale (VAS) score or disagreeing with the use of patient controlled analgesia; * presence of a pacemaker; * patients with severe CNS diseases or severe mental disorders; * operations requiring enterostomy or converts to laparotomy; * patients who need to be transferred to the intensive care unit (ICU) for treatment after surgery.

Design outcomes

Primary

MeasureTime frameDescription
The total sufentanil consumption postoperatively3 daysmeasured from the recovery area until postoperative day 3

Secondary

MeasureTime frameDescription
Pain scores (VAS)4 daysmeasured by Visual Analogue Scale( VAS ), which is a scale created in the range of 0 to 10 cm. According to the scale, 0 cm means no pain, and 10 cm means unbearable pain. On the scale, 1 to 3 cm indicates mild pain, 4 to 6 cm indicates moderate pain, and 7 to 10 cm indicates severe pain.
Pain Catastrophizing5 daysmeasured by Pain Catastrophizing Scale(PCS), which contains 13 items in three dimensions: rumination, magnification, and helplessness. Patients can answer on a 0-to-4 likert scale (0 = not at all and 4 = all the time). PCS scores range from 0 to 52, and the higher the score,the higher the frequency of catastrophizing cognitions.
Quality of recovery5 daysmeasured by Quality of Recovery (QoR)-15 questionnaire, which consists of 15 questions distributed on two dimensions: physical and mental well-being. The patients report their experiences on a scale from 0 (=not at all) to 10 (=all the time), where negatively loaded questions are reversed. This gives a maximum score = 150.
The variation of C-reactive protein(CRP)3 daysthe values of C-reactive protein from peripheral blood
Procalcitonin(PCT)3 daysthe values of procalcitonin from peripheral blood
The variation of white blood cell count (WBC)3 daysthe values of white blood cell count from peripheral blood
The number of postoperative rescue analgesia7 daysmeasured from the recovery area until discharge
Time to first ambulationup to 7 daystime to first ambulation in hours is used
Time to first flatusup to 7 daystime to first flatus in hours is used
Time to first defecation7 daystime to first defecation in hours is used
Time to first feedup to 7 daystime to first feed in hours is used
The incidence rate of adverse reaction7 daysadverse reaction includes PONV、abdominal distension、 diarrhea、difficult defecation ect.
Satisfaction score with pain management7 daysmeasured by 5-point Likert scale, 1 represents very dissatisfied while 5 represents very satisfied
Neutrophil ratio(NEUT)3 daysneutrophil ratio from peripheral blood

Countries

China

Contacts

Primary ContactGuoxin Li, M.D.,Ph.D.
gzliguoxin@163.com+86 13802771450
Backup ContactFang Qin, MS.N.
qf_smu@163.com+86 15018410013

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026